For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that. 

Osteosarcoma is an aggressive bone cancer characterized by high rate of recurrence and metastasis. In a new study, researchers show that restoring the RNA-editing enzyme adenosine deaminase acting on RNA 2 (ADAR2) slows tumor growth, reduces invasion, promotes bone-like differentiation, and improves chemotherapy sensitivity in cell and mouse models. The findings identify IGFBP7 RNA editing as a key mechanism underlying these effects, highlighting a potential differentiation-based treatment strategy for pediatric patients with bone cancer.

Researchers have created an innovative paper-based analytical device that can detect microRNA-21—a biomarker associated with multiple cancers—using only a smartphone camera for readout, demonstrating a cost-effective platform with potential for point-of-care cancer diagnostics.